On May 16, the FDA approved Fragmin (dalteparin sodium) injection to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.
Read more at fda.gov.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
